Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · Parmax Pharma Limited · 22 September 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
Parmax Pharma Limited
BSE: 540359
BSE: 540359
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Parmax Pharma Limited
StateQ4 FY26 filed
Last close₹—
Market cap₹—k cr
TTM P/E · P/B · EV/EBITDA— · — · —
Parmax Pharma Limited is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 18 | 15 | 11 | 28 | 12 |
| EBITDA (ex other income) | 3 | 2 | (3) | (1) | (4) |
| margin % | 14.0 | 14.6 | (30.5) | (2.9) | (30.0) |
| Owners' profit | 0 | (0) | (6) | (2) | (4) |
| EPS, as reported (₹) | 0.38 | (0.28) | (15.37) | 5.60 | 11.12 |
| ROE % · ROCE % | 2.4 · 6.5 | (1.8) · 4.0 | (5461.1) · (82.3) | 105.3 · (31.7) | 67.7 · (85.8) |
| Debt / equity (x) | 0.76 | 0.76 | 56.09 | (3.87) | (1.87) |
| Cash from operations | 1 | 0 | (0) | (1) | (2) |
| Capex | 0 | (1) | (2) | (1) | (1) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Parmax Pharma Limited · 22 September 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 9 | 6 | 5 | 2 | 3 | 4 | 3 |
| Profit before tax | 0 | (0) | (0) | (2) | (1) | (2) | (1) | (2) |
| Net profit | 0 | (0) | (0) | (1) | (1) | (2) | (1) | (1) |
| EPS (₹) | 0.03 | (0.58) | (1.05) | 4.00 | 2.04 | 5.56 | 1.96 | 1.56 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,49,869 | 37.2 | 5.36 | 24.1 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,49,683 | 85.5 | 14.90 | 64.4 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,282 | 79.4 | 9.57 | 41.6 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,16,367 | 26.0 | 3.93 | 15.0 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,11,403 | 33.0 | 3.23 | 17.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,08,995 | 99.6 | 20.07 | 60.7 | 16.4 | 17.2 | 7.2 | 32.0 |
| MANKIND PHARMA LIMITED | 1,00,400 | 49.1 | 6.06 | 27.6 | 11.7 | 10.8 | — | 27.3 |
| DR. REDDY S LABORATORIES | 1,00,367 | 31.1 | 2.63 | 13.5 | 10.9 | 13.0 | 12.1 | 15.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 12.3 | 29.6 | 33 of 170 | 81% |
| ROCE | (108.8) | 10.8 | 181 of 183 | 1% |
| ROE | 67.7 | 10.4 | 3 of 171 | 99% |
| Debt / Equity | (1.9) | 0.1 | 2 of 171 | 99% |
| EBITDA margin | (46.0) | 17.5 | 164 of 165 | 1% |
| Revenue growth | (31.4) | 16.3 | 149 of 161 | 8% |
| Profit growth | 60.9 | 30.9 | 54 of 158 | 66% |
| Market cap | 61 | 770 | 143 of 184 | 22% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Parmax Pharma Limited · 22 September 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Sept 2026 · Annual Report FY2025-26 and Notice of 32nd AGM on Sept 29, 2026 | board shareholder meetings | medium | — | — |
| 7 Sept 2026 · Parmax Pharma 32nd AGM on Sept 29, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 29 Aug 2026 · Parmax Pharma allots shares and warrants on preferential basis | fund raising | high | — | — |
| 24 Aug 2026 · New promoter group takes over Parmax Pharma with 30.80 percent stake acquisition | ownership changes | medium | — | — |
| 24 Aug 2026 · Post Offer Advertisement published for Parmax Pharma open offer | compliance | minimal | — | — |
| 22 Aug 2026 · In-Principle Approval for Preferential Issue of Shares and Warrants | fund raising | high | — | — |
| 17 Aug 2026 · Quarterly results published in English and Gujarati newspapers | compliance | minimal | — | — |
| 17 Aug 2026 · Promoters exit Parmax Pharma completely with 30.81 percent stake sale via off-market deal | ownership changes | high | — | — |
| 17 Aug 2026 · Non-promoter group acquires 58% stake in Parmax Pharma via off-market SPA | ownership changes | high | — | — |
| 14 Aug 2026 · Parmax Pharma: Acquirer group buys 11.52 lakh shares, stake crosses 50 percent | ownership changes | high | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in